In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment.

 

Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy.  He is the chair of the high-grade lymphoma study group and co-chairs the national CAR-T panel.

Episode ID: 1000711852206

GUID: BSHSIGS.podbean.com/67f710a0-2f6b-3970-acfc-2df2646b7c1a

Release Date: 06/06/2025, 21:30:00